United Therapeutics, the Research Triangle Park biotech with a campus in the Triangle, is touting what its leaders call a major win in pulmonary arterial hypertension: an oral drug candidate that sharply cut disease progression in a pivotal trial. The company says the pill could become a multibillion-dollar product and a direct challenger to Johnson & Johnson’s Uptravi, and local investors, clinicians and life science officials are already gaming out what a successful FDA review could mean for patients and for the Triangle’s biotech economy.
In its long-term Phase 3 ADVANCE OUTCOMES study, United Therapeutics reported that ralinepag met its primary endpoint, reducing the risk of a clinical-worsening event by 55 percent, and said it intends to submit a New Drug Application to the FDA by the second half of 2026, according to United Therapeutics. The company told Triangle Business Journal that ralinepag could eventually generate about $2 billion in annual sales, a projection that has investors and analysts recalibrating expectations for the oral prostacyclin market.
Trial Results And How They Stack Up
The ADVANCE OUTCOMES trial enrolled roughly 687 patients in an event-driven design, and ralinepag cut the risk of clinical worsening by 55 percent compared with placebo, for a hazard ratio of 0.45, with statistically significant gains in six-minute walk distance and NT-proBNP, as reported by FierceBiotech. Those effects were seen on top of standard background therapy, and company leaders are playing up ralinepag’s once-daily dosing as a convenience edge over twice-daily competitors like Uptravi.
How Big The Prize Could Be
At recent investor and analyst gatherings, United Therapeutics executives and Wall Street watchers have pointed to what they see as a sizable opening for a best-in-class oral prostacyclin. Some analysts peg potential peak sales in the neighborhood of $2 billion, according to coverage of the company’s TD Cowen presentation by Investing.com. Market analysis suggests the global PAH market is currently only in the low single digit billions, so a $2 billion product would claim a hefty slice of that pie, according to DCFModeling.
What It Means For The Triangle
United Therapeutics is counted among the major life science employers in Research Triangle Park and has put money into both manufacturing and R&D facilities in the region, according to Research Triangle Park. That kind of footprint means a successful ralinepag launch would not only influence how PAH is treated, it could also fuel new hiring and contract work up and down the Triangle’s network of suppliers, service firms and research partners.
What’s Next
United Therapeutics says it plans to present full ADVANCE OUTCOMES data at an upcoming international conference and to move toward an FDA filing later this year, with full regulatory materials still expected in the second half of 2026, per United Therapeutics. “These results mark a significant advancement for PAH patients,” CEO Martine Rothblatt said in the release. From here, investors, clinicians and insurers will be watching the full dataset, the company’s back-and-forth with the FDA, and ultimately how payors decide to treat an oral, once-daily prostacyclin that wants to go toe to toe with J&J.
